CooperSurgical and NYU Langone Fertility Center Announce Study Data Showing Significant Increase in Ongoing Pregnancy and Liv...
October 19 2020 - 2:11PM
CooperSurgical and NYU Langone Fertility Center (NYULFC), part of
The Prelude Network, announced today independent study results
demonstrating increased ongoing pregnancy and live birth rates
associated with the use of CooperSurgical's PGTai 2.0 technology to
screen embryos for in vitro fertilization (IVF).1 This
single-center study was conducted by NYULFC; and results were
presented today at the American Society of Reproductive Medicine
(ASRM) Virtual Scientific Congress.
Preimplantation Genetic Testing for aneuploidy (PGT-A) is
performed on embryos produced through IVF; it provides genetic
information to help identify embryos that are more likely to result
in a successful pregnancy. PGTai 2.0 is an advancement in PGT-A
testing that utilizes artificial intelligence to increase
objectivity of this screening process.
“This research moves us an important step closer to our goal of
increased live births, improved pregnancy outcomes and further
reduction of multiples in pregnancy through greater confidence in
single embryo transfer,” said James A. Grifo, M.D., Ph.D.,
Director, NYU Langone Fertility Center.
An estimated 48.5 million couples – approximately 15% of couples
-- are affected by infertility worldwide.2 80,000 babies were born
with IVF in 2017 in the United States3 and more than one million
babies were born in the period 1987 to 2015 in the United States as
a result of IVF.4
“The study is a demonstration of CooperSurgical’s commitment to
developing the most advanced technology in the field of genetic
testing to advance reproductive medicine and help families,” said
Tony Gordon, Vice President of Business Development,
CooperGenomics. “By applying artificial intelligence in the
PGTaism2.0 technology, we leverage mathematical algorithms derived
from real-world data to achieve objective embryo assessment.”
About the Study The
retrospective study included data from more than 700 patients in
the NYU Langone Fertility Center in New York, N.Y.
The study compared results from three next generation sequencing
(NGS) genetic tests: Standard NGS, NGS with first generation
artificial intelligence (PGTai 1.0 Technology Platform) and NGS
with second generation artificial intelligence (PGTai 2.0
Technology Platform). The ongoing pregnancy and live birth rates
significantly increased by a relative 13 percent in the PGTai 2.0
group as compared to subjective and prior methodologies.
Study results also suggest that the increase in ongoing
pregnancy and live births may be linked to improvements in several
preceding IVF outcomes (implantation rates, clinical pregnancy
rates and pregnancy loss).
About NYU Langone Fertility CenterNYU Langone
Fertility Center provides world class science and exceptional
clinical care to patients seeking fertility treatment. For over 25
years, the Fertility Center has been on a mission to help educate
women and men about their reproductive health, and to deliver
data-driven guidance at each step in the fertility care process.
NYU Langone Fertility Center is proud to serve all families with
compassionate, individualized, and cost-effective treatment
options.
The Fertility Center has helped thousands of patients realize
their dreams of having a family, and its dedicated physicians have
over 125 years of collective experience performing IVF. Each
physician is certified in Reproductive Endocrinology and
Infertility (REI) with the American Board of Obstetrics and
Gynecology, and many of its physicians also hold Professor or
Assistant Professor positions within the Department of Obstetrics
and Gynecology at NYU Langone Health. While they are physicians
first and foremost, the Fertility Center’s physicians are also
active participants in clinical research to advance the safety,
success, and affordability of fertility care.
About CooperSurgical CooperSurgical is a leader
in delivering innovative assisted reproductive technology and
genomic solutions that enhance the work of ART professionals to the
benefit of families. Its experience working with embryologists and
IVF professionals across the globe, and offering a portfolio of
products for the entire ART process, means that it can help meet
the exacting needs of ART clinics.
CooperSurgical is a wholly-owned subsidiary of CooperCompanies
(NYSE: COO). CooperSurgical headquartered in Trumbull, CT, produces
and markets a wide array of products and services for use by
women’s health care clinicians. More information can be found at
fertility.coopersurgical.com.
About CooperCompaniesCooperCompanies ("Cooper")
is a global medical device company publicly traded on the NYSE
(NYSE:COO). Cooper operates through two business units,
CooperVision and CooperSurgical. CooperVision brings a refreshing
perspective on vision care with a commitment to developing a wide
range of high-quality products for contact lens wearers and
providing focused practitioner support. CooperSurgical is committed
to advancing the health of women, babies and families with its
diversified portfolio of products and services focusing on medical
devices and fertility & genomics. Headquartered in San Ramon,
CA, Cooper has a workforce of more than 12,000 with products sold
in over 100 countries. For more information, please visit
www.coopercos.com.
Contacts:
CooperSurgicalCaren BegunGreen Room
Communications201-396-8551caren@greenroompr.com
NYU Langone Fertility CenterMia HumphreysKrupp
Kommunications239-297-6592Mhumphreys@kruppnyc.com
________________________________1 Buldo-Licciardi J, Large M,
McCulloh D, McCaffrey C, Grifo J. Second generation artificial
intelligence technology for preimplantation genetic testing (PRT)
improves pregnancy outcomes in single thawed euploid embryo
transfer cycles (STEET). Presented at American Society for
Reproductive Medicine on October 19, 2020. Available at:
https://asrm.confex.com/asrm/2020/meetingapp.cgi/Paper/8645.
Accessed October 13, 2020.2 Agarwal A, Mulgund A, Hamada A, Chyatte
MR. A unique view on male infertility around the globe. Reprod Biol
Endocrinol. 2015;13:37. Published 2015 Apr 26.
doi:10.1186/s12958-015-0032-1. Accessed October 13, 2020. 3 Centers
for Disease Control and Prevention. ART Success Rates. Available
at: https://www.cdc.gov/art/artdata/index.html. Accessed October
13, 2020.4 Centers for Disease Control and Prevention, American
Society for Reproductive Medicine, Society for Assisted
Reproductive Technology. 2015 Assisted Reproductive Technology
National Summary Report. Available at:
https://www.cdc.gov/art/pdf/2015-report/ART-2015-National-Summary-Report.pdf.
Accessed October 13, 2020.
Cooper Companies (NYSE:COO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cooper Companies (NYSE:COO)
Historical Stock Chart
From Sep 2023 to Sep 2024